NYSE$HI

Hillenbrand Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Hillenbrand's Q3 2020 results were announced, showcasing a significant revenue increase due to the Milacron acquisition, alongside solid operating results amidst a challenging market environment.

Hillenbrand reported a 36% increase in revenue to $608 million, driven by the acquisition of Milacron. GAAP EPS decreased by 33% to $0.32, while adjusted EPS increased by 25% to $0.81. The company is increasing its Milacron cost synergy target and exiting the TerraSource and Flow Control businesses.

  • Revenue increased 36% year over year to $608 million due to the addition of Milacron.
  • Adjusted EPS increased 25% to $0.81, driven by Milacron and Batesville.
  • Order backlog increased 20% year over year to $1.12 billion.
  • Milacron 3-year cost synergy target increased from $50 million to $75 million.

Headline financials

Total Revenue

$608M

Previous: $447M+36.0%
EPS (adj)

$0.81

Previous: $0.57+42.1%
APS Order Backlog

$1.12B

Previous: $933M+20.0%
Net Income

$24M

Previous: $30.4M-21.1%
Operating Income

$88.8M

Previous: $57.6M+54.2%
Gross Profit

$207M

Previous: $148M+39.7%
Cash & Equivalents

$263M

Previous: $64.4M+308.5%
Total Assets

$4.03B

Previous: $1.89B+113.2%
Stock-Based Comp

$3.7M

Previous: $2.9M+27.6%

Revenue & EPS history

Hillenbrand · Revenue · Quarterly

$608M

Q3 2020+36%vs Q3 2019
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Hillenbrand · $763M total across 2 segments · Q4 2023

  • Advanced Process Solutions
    $516M+57.3%
  • Molding Technology Solutions
    $247M-10.5%

Forward guidance

Hillenbrand is providing guidance for the fourth quarter of fiscal 2020, expecting relatively flat total revenue sequentially and adjusted EPS in the range of $0.60 to $0.70.

Tailwinds

  • Process Equipment Group revenue is expected to be modestly higher, driven by sequential growth in large plastics projects and aftermarket parts and service.

Headwinds

  • Milacron revenue is expected to decrease modestly.
  • Hot runner sales for medical projects related to COVID-19 are expected to decrease in the fourth quarter.
  • Injection molding sales are expected to remain weak.
  • Batesville revenue is forecasted to decrease modestly as a result of lower expected mortality associated with COVID-19.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 8 quarterly earnings reports

Historical avg

-0.6%

Avg return

Earnings day

-0.9%

Avg return

5 days after

-3.7%

Avg return

30 days after

45%

29 / 64 earnings

Positive

+18.5%

Q3 2025

Best reaction

-16.3%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026
Q4 2025+0.0%+0.3%+0.1%
Q3 2025+18.5%+26.8%+29.6%
Q2 2025-10.6%-9.5%-13.8%
Q1 2025-7.3%+1.1%-18.7%
Q4 2024+9.8%+5.3%+4.9%
Q3 2024-6.9%-14.0%-25.7%
Q2 2024-16.3%-14.5%-7.4%
Q1 2024-6.6%-2.6%+1.1%
Q4 2023-3.6%
Q3 2023-6.3%
Q2 2023-4.5%
Q1 2023-6.1%
Q4 2022+6.0%
Q3 2022-0.1%
Q2 2022-4.2%
Q1 2022+0.8%
Q4 2021+0.5%
Q3 2021+0.7%
Q2 2021-7.2%
Q1 2021+0.1%
Q4 2020+0.3%
Q3 2020+6.5%
Q2 2020+1.6%
Q1 2020-2.1%
Q4 2019-1.8%
Q3 2019-7.3%
Q2 2019-5.8%
Q1 2019+6.5%
Q4 2018-2.8%
Q3 2018+4.0%
Q2 2018-5.3%
Q1 2018+2.6%
Q4 2017+9.0%
Q3 2017+0.4%
Q2 2017+3.1%
Q1 2017-3.1%
Q4 2016+2.7%
Q3 2016-0.7%
Q2 2016-0.6%
Q1 2016-6.4%
Q4 2015-1.1%
Q3 2015+5.7%
Q2 2015+10.5%
Q1 2015-6.4%
Q4 2014+1.6%
Q3 2014+1.4%
Q2 2014-2.0%
Q1 2014+7.0%
Q4 2013+2.7%
Q3 2013-1.1%
Q2 2013-2.6%
Q1 2013-1.0%
Q4 2012+1.6%
Q3 2012+2.1%
Q2 2012+1.4%
Q1 2012+0.0%
Q4 2011+7.0%
Q3 2011-8.4%
Q2 2011-0.9%
Q1 2011-0.7%
Q4 2010-4.7%
Q3 2010-4.8%
Q3 2009-4.8%
Q2 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro